<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36726218</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2567</ISSN><JournalIssue CitedMedium="Internet"><Volume>169</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Immunology</Title><ISOAbbreviation>Immunology</ISOAbbreviation></Journal><ArticleTitle>Dual blockages of a broad and potent neutralizing IgM antibody targeting GH loop of EV-As.</ArticleTitle><Pagination><StartPage>292</StartPage><EndPage>308</EndPage><MedlinePgn>292-308</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/imm.13629</ELocationID><Abstract><AbstractText>The reported enterovirus A 71 (EVA71) vaccines and immunoglobin G (IgG) antibodies have no cross-antiviral efficacy against other enterovirus A (EV-A) which caused hand, foot and mouth disease (HFMD). Here we constructed an IgM antibody (20-IgM) based on our previous discovery to address the resistance encountered by IgG-based immunotherapy. Although binding to the same conserved neutralizing epitope within the GH loop of EV-As VP1, the antiviral breath and potency of 20-IgM are still higher than its parental 20-IgG1. The&#xa0;20-IgM blocks the interaction between the EV-As and its receptors, scavenger receptor class B, member 2 (SCARB2) and Kringle-containing transmembrane protein 1(KREMEN1) of the host cell. The&#xa0;20-IgM also neutralizes the EV-As at the post-attachment stages, including postattachment neutralization, uncoating and RNA release inhibition after internalization. Mechanistically, the dual blockage effect of 20-IgM is dependent on both a conserved site targeting and high affinity binding. Meanwhile, 20-IgM provides cross-antiviral efficacy in EV-As orally infected neonatal ICR mice. Collectively, 20-IgM and its property exhibit excellent antiviral activity with a dual-blockage inhibitory effect at both the pre- and post-attachment stages. The finding enhances our understanding of IgM-mediated immunity and highlights the potential of IgM subtype antibodies against enterovirus infections.</AbstractText><CopyrightInformation>&#xa9; 2023 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Wenbing</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0001-9210-1439</Identifier><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhongxiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhixiao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiaoyong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Shaozhong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immunology</MedlineTA><NlmUniqueID>0374672</NlmUniqueID><ISSNLinking>0019-2805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="Y">Hand, Foot and Mouth Disease</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IgM antibody</Keyword><Keyword MajorTopicYN="N">breadth</Keyword><Keyword MajorTopicYN="N">dual blockage</Keyword><Keyword MajorTopicYN="N">enterovirus A</Keyword><Keyword MajorTopicYN="N">potency</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36726218</ArticleId><ArticleId IdType="doi">10.1111/imm.13629</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Wu KX, Ng MM, Chu JJ. Developments towards antiviral therapies against enterovirus 71. Drug Discov Today. 2010;15:1041-51.</Citation></Reference><Reference><Citation>Zhang W, Huang Z, Huang M, Zeng J. Predicting severe enterovirus 71-infected hand, foot, and mouth disease: cytokines and chemokines. Mediators Inflamm. 2020;2020:9273241-11.</Citation></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. New Eng J Med. 2014;370:818-28.</Citation></Reference><Reference><Citation>Zhu F-C, Meng F-Y, Li J-X, Li X-L, Mao Q-Y, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2013;381:2024-32.</Citation></Reference><Reference><Citation>Shang L, Xu M, Yin Z. Antiviral drug discovery for the treatment of enterovirus 71 infections. Antiviral Res. 2013;97:183-94.</Citation></Reference><Reference><Citation>Lalani S, Poh CL. Flavonoids as antiviral agents for enterovirus A71 (EV-A71). Viruses. 2020;12:18.</Citation></Reference><Reference><Citation>Lim ZQ, Ng QY, Ng JWQ, Mahendran V, Alonso S. Recent progress and challenges in drug development to fight hand, foot and mouth disease. Expert Opin Drug Discov. 2020;15:359-71.</Citation></Reference><Reference><Citation>Du R, Mao Q, Hu Y, Lang S, Sun S, Li K, et al. A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge. Hum Vaccin Immunother. 2019;15:2343-50.</Citation></Reference><Reference><Citation>Deng YQ, Ma J, Xu LJ, Li YX, Zhao H, Han JF, et al. Generation and characterization of a protective mouse monoclonal antibody against human enterovirus 71. Appl Microbiol Biotechnol. 2015;99:7663-71.</Citation></Reference><Reference><Citation>Zhou B, Xu L, Zhu R, Tang J, Wu Y, Su R, et al. A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential. Antiviral Res. 2019;161:28-35.</Citation></Reference><Reference><Citation>Dang M, Wang X, Wang Q, Wang Y, Lin J, Sun Y, et al. Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71. Protein Cell. 2014;5:692-703.</Citation></Reference><Reference><Citation>Zhang X, Yang P, Wang N, Zhang J, Li J, Guo H, et al. The binding of a monoclonal antibody to the apical region of SCARB2 blocks EV71 infection. Protein Cell. 2017;8:590-600.</Citation></Reference><Reference><Citation>Yamayoshi S, Iizuka S, Yamashita T, Minagawa H, Mizuta K, Okamoto M, et al. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71. J Virol. 2012;86:5686-96.</Citation></Reference><Reference><Citation>Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15:798-801.</Citation></Reference><Reference><Citation>Jiao X-Y, Guo L, Huang D-Y, Chang X-L, Qiu Q-C. Distribution of EV71 receptors SCARB2 and PSGL-1 in human tissues. Virus Res. 2014;190:40-52.</Citation></Reference><Reference><Citation>Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15:794-7.</Citation></Reference><Reference><Citation>Ku Z, Ye X, Shi J, Wang X, Liu Q, Huang Z. Single neutralizing monoclonal antibodies targeting the VP1 GH loop of enterovirus 71 inhibit both virus attachment and internalization during viral entry. J Virol. 2015;12084:12084-95.</Citation></Reference><Reference><Citation>Gong S, Tomusange K, Kulkarni V, Adeniji OS, Lakhashe SK, Hariraju D, et al. Anti-HIV IgM protects against mucosal SHIV transmission. Aids. 2018;32:F5-f13.</Citation></Reference><Reference><Citation>Ku Z, Xie X, Hinton PR, Liu X, Ye X, Muruato AE, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021;595:718-23.</Citation></Reference><Reference><Citation>Shen C, Zhang M, Chen Y, Zhang L, Wang G, Chen J, et al. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency. Theranostics. 2019;9:210-31.</Citation></Reference><Reference><Citation>Zhu W, Liu Z, Zheng X, Li J, Lu K, Jiang X, et al. A broad and potent IgM antibody against tetra-EV-As induced by EVA71 and CVA16 co-immunization. Vaccine. 2021;39:6510-9.</Citation></Reference><Reference><Citation>Pl&#xfc;ckthun A, Krebber A, Krebber C, Horn U, Kn&#xfc;pfer U, Wenderoth R, et al., editors. Producing antibodies in Escherichia coli: from PCR to fermentation. Antibody Eng. 1996;203-52.</Citation></Reference><Reference><Citation>Brochet X, Lefranc M-P, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008;36:W503-8.</Citation></Reference><Reference><Citation>Dodev TS, Karagiannis P, Gilbert AE, Josephs DH, Bowen H, James LK, et al. A tool kit for rapid cloning and expression of recombinant antibodies. Sci Rep. 2014;4:5885.</Citation></Reference><Reference><Citation>Wienken CJ, Baaske P, Rothbauer U, Braun D, Duhr S. Protein-binding assays in biological liquids using microscale thermophoresis. Nat Commun. 2010;1:100.</Citation></Reference><Reference><Citation>Ku Z, Ye X, Huang X, Cai Y, Liu Q, Li Y, et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One. 2013;8:e57601.</Citation></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. In: Mart&#xed;n J, editor. Poliovirus: methods and protocols. New York, NY: Springer New York; 2016. p. 145-76.</Citation></Reference><Reference><Citation>Liu C-C, Chow Y-H, Chong P, Klein M. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. Vaccine. 2014;32:6177-82.</Citation></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19:424-9.</Citation></Reference><Reference><Citation>Ren J, Wang X, Zhu L, Hu Z, Gao Q, Yang P, et al. Structures of coxsackievirus A16 capsids with native antigenicity: implications for particle expansion, receptor binding, and immunogenicity. J Virol. 2015;89:10500-11.</Citation></Reference><Reference><Citation>Zhu L, Sun Y, Fan J, Zhu B, Cao L, Gao Q, et al. Structures of coxsackievirus A10 unveil the molecular mechanisms of receptor binding and viral uncoating. Nat Commun. 2018;9:4985.</Citation></Reference><Reference><Citation>Xu L, Zheng Q, Li S, He M, Wu Y, Li Y, et al. Atomic structures of coxsackievirus A6 and its complex with a neutralizing antibody. Nat Commun. 2017;8:505.</Citation></Reference><Reference><Citation>Lee H, Cifuente JO, Ashley RE, Conway JF, Makhov AM, Tano Y, et al. A strain-specific epitope of enterovirus 71 identified by cryo-electron microscopy of the complex with fab from neutralizing antibody. J Virol. 2013;87:11363-70.</Citation></Reference><Reference><Citation>Zhu L, Xu K, Wang N, Cao L, Wu J, Gao Q, et al. Neutralization mechanisms of two highly potent antibodies against human enterovirus 71. mBio. 2018;9(4):e01013-8.</Citation></Reference><Reference><Citation>Staring J, van den Hengel LG, Raaben M, Blomen VA, Carette JE, Brummelkamp TR. KREMEN1 is a host entry receptor for a major group of enteroviruses. Cell Host Microbe. 2018;23:636-643.e635.</Citation></Reference><Reference><Citation>Cui Y, Peng R, Song H, Tong Z, Qu X, Liu S, et al. Molecular basis of coxsackievirus A10 entry using the two-in-one attachment and uncoating receptor KRM1. Proc Natl Acad Sci. 2020;117:18711-8.</Citation></Reference><Reference><Citation>Yamayoshi S, Fujii K, Koike S. Scavenger receptor b2 as a receptor for hand, foot, and mouth disease and severe neurological diseases. Front Microbiol. 2012;3:32.</Citation></Reference><Reference><Citation>Zhou D, Zhao Y, Kotecha A, Fry EE, Kelly JT, Wang X, et al. Unexpected mode of engagement between enterovirus 71 and its receptor SCARB2. Nat Microbiol. 2019;4:414-9.</Citation></Reference><Reference><Citation>Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y, et al. Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J Biol Chem. 2012;287:6406-20.</Citation></Reference><Reference><Citation>Zhao Y, Zhou D, Ni T, Karia D, Kotecha A, Wang X, et al. Hand-foot-and-mouth disease virus receptor KREMEN1 binds the canyon of coxsackie virus A10. Nat Commun. 2020;11:38.</Citation></Reference><Reference><Citation>Ren J, Wang X, Hu Z, Gao Q, Sun Y, Li X, et al. Picornavirus uncoating intermediate captured in atomic detail. Nat Commun. 2013;4:1929.</Citation></Reference><Reference><Citation>Yamayoshi S, Ohka S, Fujii K, Koike S. Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol. 2013;87:3335-47.</Citation></Reference><Reference><Citation>Fujii K, Sudaka Y, Takashino A, Kobayashi K, Kataoka C, Suzuki T, et al. VP1 amino acid residue 145 of enterovirus 71 is a key residue for its receptor attachment and resistance to neutralizing antibody during cynomolgus monkey infection. J Virol. 2018;92:e00682-18.</Citation></Reference><Reference><Citation>Lim XF, Jia Q, Khong WX, Yan B, Premanand B, Alonso S, et al. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One. 2012;7:e29751.</Citation></Reference><Reference><Citation>Meeker TC, Lowder J, Maloney DG, Miller RA, Thielemans K, Warnke R, et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood. 1985;65:1349-63.</Citation></Reference><Reference><Citation>Parray HA, Shukla S, Samal S, Shrivastava T, Ahmed S, Sharma C, et al. Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. Int Immunopharmacol. 2020;85:106639.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>